NEW YORK (GenomeWeb News) - Gene therapy company Oxford Biomedica said today that it has licensed the rights for RNA interference technology from the University of Massachusetts Medical School and the Carnegie Institute of Washington. 
 
Under the agreement, Oxford Biomedica receives non-exclusive rights under the Carnegie and UMSS licensing programs for the RNAi technology and exclusive rights for the technology’s gene therapy applications using lentiviral vectors.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.